SEP 08, 2016 01:30 PM PDT

The Paradigm Shift in Clinical Microbiology

  • Scientific Affairs Manage, Roche
      Steven is currently a Scientific Affairs Manager within the Medical and Scientific Affairs organization. He is responsible for interfacing with clinicians and key opinion leaders to assist in commercialization of products within the Roche Molecular Diagnostics portfolio. Steven has expertise in Donor Screening using both the cobas s201 platform as well as the cobas 6800 and 8800. He is also the lead for the Microbiology assays for Molecular MSA.

      Steven has worked at Roche for 5 years in several capacities. He worked directly with customers as part of Global Customer Support by handling complaints as well as assisting customers on site. He has also worked as part of the Operations Investigation Unit to perform quality investigations related to all kits and components manufactured at RMS. Steven has a bachelor's degree in Biotechnology from Rutgers University and a Ph.D. in Microbiology and Molecular Genetics from the University of Medicine and Dentistry of New Jersey.

      Steven currently lives with his wife, Marta, in Raritan, New Jersey.


    Multi-Drug Resistant Organisms (MDROs) are becoming a bigger and bigger concern throughout the world. Antibiotic resistance forms and spreads faster than pharmaceutical companies have been able to develop new antibiotic compounds. This stagnation in the development of new tools for the clinical laboratory to identify these organisms has equally been a problem. The traditional methods we use to identify and determine antibiotic resistance and susceptibility have not significantly changed for at least 50 years. Although these techniques are effective, they continue to require highly skilled staff, and multiple days to get a definitive result. Novel technologies, like Smarticles, are in development today with the goal to help identify drug resistant organisms the same day that samples are collected with automated systems. Technologies like Smarticles provide the promise of significantly improving our ability to identify carriers of these organisms and prevent them from spreading to other patients in the hospital.
    Dr. Cagas will give an overview of the growing threat that MDROs pose, how Clinical Microbiology has evolved to where it is today, and how novel technologies, like Smarticles, have the potential to cause a significant paradigm shift for clinical laboratories and the hospitals they serve.

    Show Resources
    Loading Comments...